203 related articles for article (PubMed ID: 27285281)
1. A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas.
Fiedler W; DeDosso S; Cresta S; Weidmann J; Tessari A; Salzberg M; Dietrich B; Baumeister H; Goletz S; Gianni L; Sessa C
Eur J Cancer; 2016 Aug; 63():55-63. PubMed ID: 27285281
[TBL] [Abstract][Full Text] [Related]
2. Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8.
Dian D; Lenhard M; Mayr D; Heublein S; Karsten U; Goletz S; Kuhn C; Wiest I; Friese K; Weissenbacher T; Jeschke U
Histol Histopathol; 2013 Feb; 28(2):239-44. PubMed ID: 23275306
[TBL] [Abstract][Full Text] [Related]
3. Immunoreactivity of the fully humanized therapeutic antibody PankoMab-GEX™ is an independent prognostic marker for breast cancer patients.
Heublein S; Mayr D; Egger M; Karsten U; Goletz S; Angele M; Gallwas J; Jeschke U; Ditsch N
J Exp Clin Cancer Res; 2015 May; 34(1):50. PubMed ID: 25986064
[TBL] [Abstract][Full Text] [Related]
4. Expression of the Tumor-associated Mucin 1 Epitope Analyzed with the Humanized PankoMab-GEX™ Antibody in Malignant and Normal Tissues of the Head and Neck.
Wiest I; Alexiou C; Friese K; Betz P; Tübel J; Goletz S; Dian D; Jeschke U
Anticancer Res; 2016 Jun; 36(6):3179-84. PubMed ID: 27272845
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer.
Pegram MD; Borges VF; Ibrahim N; Fuloria J; Shapiro C; Perez S; Wang K; Schaedli Stark F; Courtenay Luck N
Breast Cancer Res; 2009; 11(5):R73. PubMed ID: 19811637
[TBL] [Abstract][Full Text] [Related]
6. A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors.
Diaz LA; Coughlin CM; Weil SC; Fishel J; Gounder MM; Lawrence S; Azad N; O'Shannessy DJ; Grasso L; Wustner J; Ebel W; Carvajal RD
Clin Cancer Res; 2015 Mar; 21(6):1281-8. PubMed ID: 25398449
[TBL] [Abstract][Full Text] [Related]
7. AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors.
Frentzas S; Kao S; Gao R; Zheng H; Rizwan A; Budha N; de la Hoz Pedroza L; Tan W; Meniawy T
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857528
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours.
Fiedler W; Stoeger H; Perotti A; Gastl G; Weidmann J; Dietrich B; Baumeister H; Danielczyk A; Goletz S; Salzberg M; De Dosso S
ESMO Open; 2018; 3(4):e000381. PubMed ID: 30018811
[TBL] [Abstract][Full Text] [Related]
9. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors.
Paz-Ares LG; Gomez-Roca C; Delord JP; Cervantes A; Markman B; Corral J; Soria JC; Bergé Y; Roda D; Russell-Yarde F; Hollingsworth S; Baselga J; Umana P; Manenti L; Tabernero J
J Clin Oncol; 2011 Oct; 29(28):3783-90. PubMed ID: 21900113
[TBL] [Abstract][Full Text] [Related]
10. PankoMab: a potent new generation anti-tumour MUC1 antibody.
Danielczyk A; Stahn R; Faulstich D; Löffler A; Märten A; Karsten U; Goletz S
Cancer Immunol Immunother; 2006 Nov; 55(11):1337-47. PubMed ID: 16485130
[TBL] [Abstract][Full Text] [Related]
11. Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors.
Ochsenreither S; Fiedler WM; Conte GD; Macchini M; Matos I; Habel B; Ahrens-Fath I; Raspagliesi F; Lorusso D; Keilholz U; Rolling C; Kebenko M; Klinghammer KF; Saavedra O; Baumeister H; Zurlo A; Garralda E
ESMO Open; 2022 Apr; 7(2):100447. PubMed ID: 35397434
[TBL] [Abstract][Full Text] [Related]
12. Determination of MUC1 in sera of ovarian cancer patients and in sera of patients with benign changes of the ovaries with CA15-3, CA27.29, and PankoMab.
Jeschke U; Wiest I; Schumacher AL; Kupka M; Rack B; Stahn R; Karsten U; Mayr D; Friese K; Dian D
Anticancer Res; 2012 May; 32(5):2185-9. PubMed ID: 22593508
[TBL] [Abstract][Full Text] [Related]
13. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.
Atzori F; Tabernero J; Cervantes A; Prudkin L; Andreu J; Rodríguez-Braun E; Domingo A; Guijarro J; Gamez C; Rodon J; Di Cosimo S; Brown H; Clark J; Hardwick JS; Beckman RA; Hanley WD; Hsu K; Calvo E; Roselló S; Langdon RB; Baselga J
Clin Cancer Res; 2011 Oct; 17(19):6304-12. PubMed ID: 21810918
[TBL] [Abstract][Full Text] [Related]
14. A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors.
Chiorean EG; LoRusso P; Strother RM; Diamond JR; Younger A; Messersmith WA; Adriaens L; Liu L; Kao RJ; DiCioccio AT; Kostic A; Leek R; Harris A; Jimeno A
Clin Cancer Res; 2015 Jun; 21(12):2695-703. PubMed ID: 25724527
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors.
Denlinger CS; Keedy VL; Moyo V; MacBeath G; Shapiro GI
Invest New Drugs; 2021 Dec; 39(6):1604-1612. PubMed ID: 34250553
[TBL] [Abstract][Full Text] [Related]
16. A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors.
Huang Z; Xu Y; Hong W; Gong L; Chen K; Qin J; Xie F; Wang F; Tian X; Meng X; Feng W; Li L; Zhang B; Kang X; Fan Y
Front Immunol; 2023; 14():1258573. PubMed ID: 37936687
[TBL] [Abstract][Full Text] [Related]
17. A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors.
Doi T; Shitara K; Kojima T; Yoshino T; Dontabhaktuni A; Rebscher H; Tang S; Cosaert J; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1253-62. PubMed ID: 27139036
[TBL] [Abstract][Full Text] [Related]
18. A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
Falchook GS; Peeters M; Rottey S; Dirix LY; Obermannova R; Cohen JE; Perets R; Frommer RS; Bauer TM; Wang JS; Carvajal RD; Sabari J; Chapman S; Zhang W; Calderon B; Peterson DA
Invest New Drugs; 2021 Oct; 39(5):1284-1297. PubMed ID: 33852104
[TBL] [Abstract][Full Text] [Related]
19. A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors.
Becerra CR; Conkling P; Vogelzang N; Wu H; Hong S; Narwal R; Liang M; Tavakkoli F; Pandya N
Cancer Chemother Pharmacol; 2014 Nov; 74(5):917-25. PubMed ID: 25149088
[TBL] [Abstract][Full Text] [Related]
20. Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.
Aftimos P; Rolfo C; Rottey S; Offner F; Bron D; Maerevoet M; Soria JC; Moshir M; Dreier T; Van Rompaey L; Michot JM; Silence K; Hultberg A; Gandini D; de Haard H; Ribrag V; Peeters M; Thibault A; Leupin N; Awada A
Clin Cancer Res; 2017 Nov; 23(21):6411-6420. PubMed ID: 28765328
[No Abstract] [Full Text] [Related]
[Next] [New Search]
